Patient Preference Research
Patient preference studies provide a means of collecting insights into aspects of treatment that are most important to patients and the trade-offs between various treatment characteristics and attributes that patients are willing to make. This may include trade-offs between the efficacy, safety profiles of manner in which treatments are administered (e.g. route, frequency). Patient preference data can be used to strengthen patient-centric decision-making throughout the medical product lifecycle. Accordingly, there is increasing interest in patient preference information among regulatory authorities, healthcare providers and patients themselves.
- Inform treatment design/features
- Explore unmet needs
- Refine treatment design, target population
- Define target treatment profile
- Endpoint selection
- Trial size
- Preference endpoints
- Communicate value to payers, HCP, patients
- Shared decision making tools
It is important that preference studies are designed to evaluate treatment attributes that are important within the decision-making context and do so in a manner that is consistently understood by participants. As experts in understanding and evaluating the patient perspective, Adelphi have experience in optimizing the design of preference studies by translating complex medical information into ways that can be readily understood by participants and generate meaningful insights for stakeholders.
Adelphi Values have experience in a range of stated preference methods (including discrete choice experiments, best-worst scaling and other ranking, rating and indifference methods) and can advise, design and execute studies depending on client needs; whether this be to facilitate the development of new drugs and devices, support benefit-risk evaluation as part of regulatory approval, inform value assessment/reimbursement or assist patient and/or clinical decision-making.
We employ best practice methodologies endorsed by regulators (e.g., Food and Drug Administration; FDA and European Medicines Agency; EMA), reimbursement authorities (e.g., The National Institute for Health and Care Excellence; NICE, The Canadian Agency for Drugs and Technologies in Health; CADTH) and specialist methods groups (e.g., IMI-Prefer). With experience across a variety of indications, we also have experience of interacting direct with various stakeholders (including patient advocacy groups, regulatory authorities and payers) to ensure that the design of the study meets their needs. or assist patient or clinical decision-making.